Delcath Systems vs TELA Bio
Delcath Systems reported revenue of $85 million in fiscal 2025, about the same as TELA Bio's $80 million in fiscal 2025. Delcath Systems' revenue grew 129.1% in its latest year, and TELA Bio's grew 15.8%. Delcath Systems had an operating margin of 0.8%, against -42.0% at TELA Bio. Free cash flow was $21 million at Delcath Systems and −$29 million at TELA Bio.
Side by side
| Delcath Systems | TELA Bio | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $85M | $80M |
| Revenue growth | 129.1% | 15.8% |
| Revenue growth a year, last 5 years | — | 34.6% |
| Gross margin | 86.2% | 67.7% |
| Operating margin | 0.8% | −42.0% |
| Net margin | 3.2% | −48.4% |
| Free cash flow | $21M | −$29M |
| Free cash flow margin | 24.6% | −35.7% |
| Return on capital | 2.8% | −190.2% |
| Net debt to EBITDA | −101.4x | — |
| Dividends and buybacks | $6M | $0M |
| Change in diluted share count | 40.0% | 64.6% |
| Last close | $19.24 | $0.73 |
| P/E at the last close | 120.2× | — |
| Insider trades, last 12 months | bought $189,362, sold $0 | bought $186,250, sold $0 |
| Piotroski F-score | 6 of 9 | 4 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Delcath SystemsTELA Bio
Operating margin
Percent of revenue
Delcath SystemsTELA Bio
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Delcath SystemsTELA Bio
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Delcath Systems and TELA Bio pages.